DIFFERENTIAL INHIBITION BY LOW-DOSE ASPIRIN OF HUMAN VENOUS PROSTACYCLIN SYNTHESIS AND PLATELET THROMBOXANE SYNTHESIS
- 1 May 1981
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 317 (8227), 969-971
- https://doi.org/10.1016/s0140-6736(81)91733-5
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group.Circulation, 1980
- ASPIRIN AND SECONDARY MORTALITY AFTER MYOCARDIAL INFARCTIONThe Lancet, 1979
- Sensitivity of fatty acid cyclooxygenase from human aorta to acetylation by aspirin.Proceedings of the National Academy of Sciences of the United States of America, 1978
- A Randomized Trial of Aspirin and Sulfinpyrazone in Threatened StrokeNew England Journal of Medicine, 1978
- Controlled trial of aspirin in cerebral ischemia.Stroke, 1977
- HUMAN ARTERIAL AND VENOUS TISSUES GENERATE PROSTACYCLIN (PROSTAGLANDIN X), A POTENT INHIBITOR OF PLATELET AGGREGATIONThe Lancet, 1977
- An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregationNature, 1976
- The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein.JCI Insight, 1975
- Acetylation of prostaglandin synthase by aspirin.Proceedings of the National Academy of Sciences of the United States of America, 1975
- Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.Proceedings of the National Academy of Sciences of the United States of America, 1975